Is Glasdegib mainly used to treat acute myeloid leukemia?

The primary indication for Glasdegib is acute myeloid leukemia (AML), particularly in elderly or frail patients who are unable to tolerate standard, powerful chemotherapy. It reduces the viability of leukemia stem cells by inhibiting the Hedgehog signaling pathway, making AML cells more sensitive to chemotherapy. The U.S. Food and Drug Administration has approved the use of Glasgib in combination with low-dose cytarabine (LDAC) for the treatment of elderly patients with newly diagnosed AML.

AML is a highly heterogeneous hematological malignant tumor, and traditional treatment methods mainly rely on high-intensity chemotherapy (such as cytarabine combined with anthracyclines). However, many older patients are unable to tolerate intense cytotoxic treatments due to poor physical condition. Therefore, targeted therapy has become an important option for these patients. The advantage of Glasgib in the treatment of AML is that it can be combined with low-dose chemotherapy to improve the response rate while reducing serious adverse reactions, allowing patients to receive longer-term treatment.

Although Glasgib is primarily used inAML, the Hedgehog signaling pathway also plays an important role in other hematological malignancies and certain solid tumors (such as pancreatic cancer, lung cancer, myelodysplastic syndromes). As a result, researchers are exploring its potential applications in other cancers. For example, some preliminary studies suggest that Glasgib may have some efficacy in certain types of myeloproliferative tumors. However, current research into these indications is still in its early stages and has not yet been widely recognized.

In general, the use of Glasgib inAML treatment has been widely recognized, especially for elderly patients who cannot tolerate high-intensity chemotherapy. In the future, as more research is conducted, the drug's indications may be further expanded, providing new treatment options for more cancer patients. For patients undergoing treatment, it is recommended to communicate with their doctors regularly, evaluate their condition, and optimize their treatment plan based on the latest treatment guidelines.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo